InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,129.60
(
-0.24%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.15
(
-0.38%
)
Bitcoin
61,048.87
(
0.39%
)
Post# of 252388
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 02/22/2007 5:32:38 PM

Thursday, February 22, 2007 5:32:38 PM

Post# of 252388
ANDS trial slippages:

ANA975 for HCV: Resumption of human trials following animal tox studies now expected to occur at the end of 2007. Previously, the guidance was 2H07.

ANA380 for HBV: Phase-2b trial now expected to start “sometime in 2007.” Previously, the guidance was 2Q07.

Source: Today’s ANDS CC

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up